This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Samimi, G. Articles by Howell, S. B. Search for Related Content PubMed PubMed Citation Articles by Samimi, G. Articles by Howell, S. B. Related Collections Commentaries

Increase in Expression of the Copper Transporter ATP7A during Platinum Drug-Based Treatment Is Associated with Poor Survival in Ovarian Cancer Patients

¹ Department of Medicine and the Cancer Center, University of California-San Diego, La Jolla, California;
² City of Hope Medical Center, Duarte, California; and
³ University of Arizona Cancer Center, Tucson, Arizona

ABSTRACT

Purpose: The Cu efflux transporter ATP7A is overexpressed in some cisplatin-resistant ovarian carcinoma cell lines. We examined the expression of ATP7A in the major normal human organs and in several types of human malignancies and sought to determine whether ATP7A expression changed during treatment of ovarian carcinomas with Pt-containing regimens.

Experimental Design: ATP7A expression was quantified by immunohistochemical staining using microarrays containing normal and malignant tissues, and standard sections of 54 paired tumor samples obtained from ovarian carcinoma patients before and after at least two cycles of platinum-based therapy.

Results: ATP7A was expressed in normal endometrium, prostate, testis, and kidney but was not detected in the other major organs. ATP7A was expressed in some of the most common human malignancies, including prostate (7 of 7), breast (10 of 10), lung (8 of 8), colon (5 of 8), and ovary (6 of 7), as well as in a wide variety of other types of malignancy. ATP7A staining was detected in 28 of 54 ovarian carcinomas before treatment. Patients with increased ATP7A expression after treatment (18 of 54) exhibited poorer actuarial survival (P < 0.0057 by log-rank test). Expression of ATP7A either before or after treatment was not associated with other clinical factors.

Conclusions: Although ATP7A is not detectable in most normal tissues it is expressed in a considerable fraction of many common tumor types. Enrichment of the tumor for ATP7A-expressing cells during platinum drug-based treatment of ovarian cancers is associated with poor survival. These findings are in agreement with results of in vitro studies from this laboratory demonstrating that increased expression of ATP7A renders cells resistant to cisplatin and carboplatin.

Commentaries

Lustrous Insights into Cisplatin Accumulation: Copper Transporters

Gary D. Kruh
Clin. Cancer Res. 2003 9: 5807-5809. [Full Text] [PDF]

This article has been cited by other articles:

				B. G. Blair, C. A. Larson, R. Safaei, and S. B. Howell Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin Clin. Cancer Res., July 1, 2009; 15(13): 4312 - 4321. [Abstract] [Full Text] [PDF]

				J. Song, I.-m. Shih, R. Salani, D. W. Chan, and Z. Zhang Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients Clin. Cancer Res., November 15, 2007; 13(22): 6842 - 6849. [Abstract] [Full Text] [PDF]

				S. Lutsenko, N. L. Barnes, M. Y. Bartee, and O. Y. Dmitriev Function and Regulation of Human Copper-Transporting ATPases Physiol Rev, July 1, 2007; 87(3): 1011 - 1046. [Abstract] [Full Text] [PDF]

				S. Owatari, S. Akune, M. Komatsu, R. Ikeda, S. D. Firth, X.-F. Che, M. Yamamoto, K. Tsujikawa, M. Kitazono, T. Ishizawa, et al. Copper-Transporting P-Type ATPase, ATP7A, Confers Multidrug Resistance and Its Expression Is Related to Resistance to SN-38 in Clinical Colon Cancer Cancer Res., May 15, 2007; 67(10): 4860 - 4868. [Abstract] [Full Text] [PDF]

				R. Safaei, K. Katano, B. J. Larson, G. Samimi, A. K. Holzer, W. Naerdemann, M. Tomioka, M. Goodman, and S. B. Howell Intracellular Localization and Trafficking of Fluorescein-Labeled Cisplatin in Human Ovarian Carcinoma Cells Clin. Cancer Res., January 15, 2005; 11(2): 756 - 767. [Abstract] [Full Text] [PDF]

				G. Samimi, R. Safaei, K. Katano, A. K. Holzer, M. Rochdi, M. Tomioka, M. Goodman, and S. B. Howell Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells Clin. Cancer Res., July 15, 2004; 10(14): 4661 - 4669. [Abstract] [Full Text] [PDF]

				G. D. Kruh Lustrous Insights into Cisplatin Accumulation: Copper Transporters Clin. Cancer Res., December 1, 2003; 9(16): 5807 - 5809. [Full Text] [PDF]